CRISPR and Cas Genes Market to Grow with a CAGR of 16.28% through 2029F
Increasing
investment by biotechnology companies for novel therapeutics is expected to
drive the Global CRISPR and Cas Genes Market growth in the forecast
period, 2025-2029.
According
to TechSci Research report, “CRISPR and Cas Genes Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”,
the Global CRISPR and Cas Genes Market stood at USD 2.40 Billion in
2023 and is anticipated to project steady growth in the forecast period with a
CAGR of 16.28% through
2029. The therapeutic application of CRISPR-Cas technology has emerged as a
major driving force behind the growth of the global CRISPR and Cas genes
market. CRISPR-Cas systems offer unparalleled precision and efficiency in
editing the genetic material of living organisms, holding immense promise for
the treatment of genetic disorders, infectious diseases, and various forms of
cancer. One of the most significant trends within this domain is the increasing
focus on developing CRISPR-based therapies for rare genetic diseases.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
"Global CRISPR and Cas Genes Market”
In recent years, numerous clinical
trials have been initiated to evaluate the safety and efficacy of CRISPR-based
therapies in humans. These trials span a wide range of indications, including
sickle cell disease, beta-thalassemia, cystic fibrosis, and muscular dystrophy,
among others. The successful completion of early-phase clinical trials and the
promising results observed in preclinical studies have bolstered investor
confidence and attracted substantial investments in the field.
Collaborations and
partnerships between biopharmaceutical companies, academic institutions, and
research organizations have accelerated the development and commercialization
of CRISPR-based therapeutics. These collaborations enable access to complementary
expertise, resources, and infrastructure, facilitating the translation of
innovative research into clinically viable treatments.
The therapeutic applications of
CRISPR-Cas technology are expected to continue expanding, driven by ongoing
advancements in genome editing techniques, improved delivery systems, and a
deeper understanding of disease biology. As regulatory agencies streamline the
approval process for gene therapies and gene editing technologies, the
commercialization of CRISPR-based therapeutics is poised to revolutionize the
treatment paradigm across various disease areas.
However,
alongside the opportunities, the market also faces challenges, including
ethical considerations, regulatory frameworks, and concerns regarding
off-target effects and unintended consequences of gene editing. Addressing
these challenges will be crucial for realizing the full potential of CRISPR-Cas
technology and ensuring its responsible and ethical deployment across various
domains.
The
Global CRISPR and Cas Genes Market is segmented into product & service,
application, end user, regional distribution, and company.
Based on the application, the biomedical application segment is anticipated
to dominate, surpassing agricultural applications, owing to several key factors
driving its growth. The biomedical application of CRISPR and Cas genes holds
immense promise for revolutionizing healthcare by offering precise and targeted
treatments for a wide range of genetic disorders, chronic diseases, and
infectious illnesses. The ability to edit genes with unprecedented accuracy
opens up avenues for developing novel therapies, personalized medicine
approaches, and advanced diagnostics. Pharmaceutical companies, biotechnology
firms, and academic institutions are actively pursuing clinical trials and
preclinical studies to evaluate the efficacy and safety of CRISPR-based
treatments for various diseases, including cancer, genetic disorders, and
infectious diseases like HIV/AIDS. Regulatory agencies are
increasingly supportive of CRISPR-based therapies, expediting the approval
process for clinical trials and commercialization. Breakthrough designations
and fast-track approvals are accelerating the development and adoption of
CRISPR-based therapeutics, further bolstering the dominance of the biomedical
segment in the market.
North America is indeed anticipated to
dominate the global CRISPR and Cas genes market, primarily due to factors such
as robust research infrastructure, substantial investments in biotechnology and
pharmaceutical sectors, and a favorable regulatory environment supporting the
development and commercialization of gene editing technologies.
As for the second most dominating
region, Europe emerges as a significant contender. Europe boasts a strong
scientific base with renowned research institutes and universities actively
engaged in CRISPR-Cas research and applications. Europe's
thriving biotechnology and pharmaceutical industries, along with increasing
investments in genomic research and personalized medicine initiatives,
contribute to the region's prominence in the global CRISPR and Cas genes
market.
Major
companies operating in Global CRISPR and Cas Genes Market are:
- AstraZeneca plc
- Addgene
- Cellectis bioresearch Inc
- CRISPR Therapeutics Inc.
- Editas Medicine, Inc.
- F. Hoffmann-La Roche Ltd.
- Horizon Discovery Group plc
- Lonza Group AG
- GenScript Biotech
Corporation
- Merck KGaA
Download Free Sample Report
Customers
can also request for 10% free customization on this report
“The
future of the CRISPR and Cas genes market holds immense promise, driven by
ongoing technological advancements, expanding applications across diverse
industries, and increasing investment. As CRISPR-Cas technology matures, it is
poised to revolutionize various sectors including healthcare, agriculture,
biotechnology, and research. In healthcare, CRISPR-based therapies offer
potential treatments for genetic disorders, cancer, and infectious diseases,
promising more precise and effective interventions. Advancements in
agricultural biotechnology utilizing CRISPR can enhance crop resilience, yield,
and nutritional value, addressing food security challenges globally.,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“CRISPR and Cas Genes Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product
& Service (Product (Kits & Enzymes, Libraries, Design Tool, Antibodies,
Others), Service (Cell Line Engineering, gRNA Design, Microbial Gene Editing,
DNA synthesis)), By Application (Biomedical, Agricultural), By End-use
(Biotechnology & Pharmaceutical Companies, Academic & Government
Research Institutes, Contract Research Organizations (CROs)), By Region and
Competition, 2019-2029F”, has evaluated the future growth potential of Global
CRISPR and Cas Genes Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global CRISPR
and Cas Genes Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com